Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients on nucleoside analogs (NAs) can be predicted using the FIB-4 index. Higher FIB-4 scores indicate increased HCC incidence, suggesting its utility for monitoring and early intervention.
Area Of Science
- Hepatology
- Oncology
- Medical Data Science
Background
- Nucleoside analogs (NAs) effectively inhibit hepatitis B virus (HBV) but do not eliminate hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients.
- A non-invasive method for predicting HCC risk in CHB patients undergoing NA treatment is needed for timely intervention.
Purpose Of The Study
- To develop and validate a non-invasive predictive model for HCC risk assessment in CHB patients receiving NA treatment.
- To evaluate the efficacy of the FIB-4 index in predicting HCC incidence over time.
Main Methods
- A retrospective cohort study of 501 CHB patients treated with NAs from 2013-2019.
- The FIB-4 index was calculated semiannually based on laboratory values.
- Patients were stratified into three groups based on FIB-4 index (<1.45, 1.45-3.25, ≥3.25) and HCC incidence was monitored using Kaplan-Meier curves.
Main Results
- HCC incidence was significantly higher in patients with a FIB-4 index ≥ 3.25 (9.09%) compared to those with < 1.45 (1.18%) and 1.45-3.25 (1.32%).
- Dynamic assessment revealed a significant increase in patients with FIB-4 < 1.45 and a decrease in those with FIB-4 ≥ 3.25 over time (P < 0.001).
- The FIB-4 index demonstrated effectiveness in predicting HCC incidence.
Conclusions
- The FIB-4 index is a valuable non-invasive tool for predicting HCC risk in CHB patients on NA therapy.
- Dynamic monitoring of the FIB-4 index allows for regular surveillance and timely intervention to reduce HCC risk.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
